DURHAM, N.C. -- Cancer patients are not waiting longer for chemotherapy, nor are they traveling greater distances to receive treatment, despite predictions of access issues when Medicare reduced payment for infusion therapy.
DURHAM, N.C., Oct. 8 -- Cancer patients are not waiting longer for chemotherapy, nor are they traveling greater distances to receive treatment, despite predictions of access issues when Medicare reduced payment for infusion therapy.
Moreover, even though more Medicare patients said they had difficulty paying out-of-pocket chemotherapy-related expenses after the Medicare cuts, 87% said they were satisfied or very satisfied with the care they received, said Kevin A. Schulman, M.D., of Duke University here, and colleagues.
The findings emerged from a survey of chemotherapy patients who received treatment before and after the 2005 implementation of the Medicare Modernization Act, which reduced the amounts reimbursed for drug acquisition and administration. Survey results were released online ahead of publication in the Nov.15 issue of Cancer.
The investigators conducted the survey via e-mail invitation to a web-based survey tool, and by paper surveys distributed at oncology practices. They received 1,421 responses -- 684 from patients treated from January 2003 through January 2005, and 737 from patients treated on or after Feb. 1, 2005 when Medicare changes were implemented.
Most respondents were white women and the mean age was 60. One-third of the sample had breast cancer, 12% had lung cancer, and 12% had lymphoma. Because the survey was limited to patients who underwent intravenous chemotherapy, prostate and other cancers that are treated primarily by surgery were underrepresented.
Among the findings for patients 65 or older:
Patients younger than 65 reported similar experiences as those 65 or older, a finding the researchers said was contrary to their expectations.
The investigators conducted separate analyses of two subgroups -- patients living in rural areas and Medicare beneficiaries without supplemental insurance.
There were significant differences in treatment location for both groups:
Sotagliflozin in Patients with Type 1 Diabetes and CKD to be Discussed at October FDA AdComm Meeting
October 14th 2024Lexicon's sotagliflozin is on the October 31 docket for discussion by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee; PDUFA goal date remains set for December 20.